首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Effect of Naoxintong Capsule in the Treatment of Patients with Cerebral Infarction and Carotid Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Trials
【24h】

The Effect of Naoxintong Capsule in the Treatment of Patients with Cerebral Infarction and Carotid Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Trials

机译:脑心通胶囊治疗脑梗死和颈动脉粥样硬化的疗效:随机试验的系统评价和荟萃分析

获取原文
           

摘要

Objective. Naoxintong capsule (NXT) has been widely used to treat patients with cerebral infarction and carotid atherosclerosis. However, it is uncertain whether there is robust evidence on the effects of NXT for cerebral infarction and carotid atherosclerosis. A systematic review and meta-analysis of randomized trials were performed to assess the efficacy of NXT in the treatment of cerebral infarction and carotid atherosclerosis. Methods. The Cochrane Library, EMBASE, the Medline database, the Wanfang database, the China National Knowledge Infrastructure, and the VIP database were searched up to January 2018 with no language restrictions. Study selection, data extraction, quality assessment, and data analyses were performed according to the Cochrane standards. Results. Eleven studies (N=1141) in total satisfied the inclusion criteria for the meta-analysis. The results of meta-analysis showed that compared with the conventional therapy alone, NXT combined with conventional therapy could significantly improve national institutes of health stroke scale (NIHSS) score (MD= -3.92, 95%CI -4.31~-3.52, P<0.00001), plaque area (MD= -0.16, 95%CI -0.20~-0.13, P<0.00001), carotid intima-media thickness (IMT) (MD= -0.23, 95%CI -0.26~-0.20, P<0.00001), total cholesterol (TC) (MD= -0.16, 95%CI -0.79~-0.42, P<0.00001), triglyceride (TG) (MD= -0.69, 95%CI -0.88~-0.51, P<0.00001), high-density lipoprotein cholesterol (HDL-C) (MD= 0.23, 95%CI 0.15~0.31, P<0.00001), and low-density lipoprotein cholesterol (LDL-C) (MD= -0.42, 95%CI -0.58~-0.25, P<0.00001). There were no reported adverse events in the studies. Conclusions. NXT is an effective and safe therapy option for patients with cerebral infarction and carotid atherosclerosis. However, due to the high clinical heterogeneity and small sample size of the included trials, further standardized preparation, large-scale and rigorously designed trials are needed.
机译:目的。脑心通胶囊(NXT)已被广泛用于治疗脑梗死和颈动脉粥样硬化的患者。然而,不确定是否有确凿的证据证明NXT对脑梗死和颈动脉粥样硬化的作用。对随机试验进行了系统的回顾和荟萃分析,以评估NXT在治疗脑梗死和颈动脉粥样硬化中的疗效。方法。检索到2018年1月的Cochrane图书馆,EMBASE,Medline数据库,Wanfang数据库,中国国家知识基础设施和VIP数据库,没有语言限制。根据Cochrane标准进行研究选择,数据提取,质量评估和数据分析。结果。总共11项研究(N = 1141)满足荟萃分析的纳入标准。荟萃分析的结果表明,与单独的常规治疗相比,NXT联合常规治疗可以显着提高美国国立卫生研究院卒中量表(NIHSS)评分(MD = -3.92,95%CI -4.31〜-3.52,P < 0.00001),斑块面积(MD = -0.16,95%CI -0.20〜-0.13,P <0.00001),颈动脉内膜中层厚度(IMT)(MD = -0.23,95%CI -0.26〜-0.20,P < 0.00001),总胆固醇(TC)(MD = -0.16,95%CI -0.79〜-0.42,P <0.00001),甘油三酸酯(TG)(MD = -0.69,95%CI -0.88〜-0.51,P <0.00001) ),高密度脂蛋白胆固醇(HDL-C)(MD = 0.23,95%CI 0.15〜0.31,P <0.00001)和低密度脂蛋白胆固醇(LDL-C)(MD = -0.42,95%CI- 0.58〜-0.25,P <0.00001)。研究中没有报道不良事件。结论。 NXT对于脑梗塞和颈动脉粥样硬化的患者是一种安全有效的治疗选择。但是,由于所纳入试验的临床异质性高和样本量小,因此需要进一步的标准化制备,大规模和严格设计的试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号